Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin mechanism study in heart failure with reduced ejection fraction
ACTRN12621000187842Phase 3Not yet recruiting
- Sponsor
- The Alfred Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Dapagliflozin with Placebo control (2 arms). Primary endpoints: Change in hemodynamics by right heart catheterization and Change in anthropometric and clinical measurements. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ACTRN12621000187842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000187842.